How important is optimal blood pressure control?

Clinical Therapeutics

Volumn 26, Issue SUPPL. A, 2004, Pages

  McInnes, Gordon T ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiotensin II receptor antagonist; Antihypertensive; Blood pressure; Diabetes; Hypertension; Sartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; LOSARTAN; SARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT;

EID: 2342463588     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90140-3     Document Type: Article

References (28)

1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003;289:2560-2572.
3. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
4. Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens. 1986;4:141-156.
5. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 DM: Implications of the Appropriate Blood Pressure Control in Dm (ABCD) trial. Am J Cardiol. 1998;82:9R-14R.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
7. UK Prospective Dm Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 DM: UKPDS 38 [published correction appears in BMJ. 1998;318:29]. BMJ. 1998;317:703-713.
8. Stamler J, Vaccaro O, Neaton JD, et al. Dm, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Dm Care. 1993;16:434-444.
9. Yusuf S, Sleight P, Pogue J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published correction appears in N Engl J Med. 2000;342:1376; 2000:342:748]. N Engl J Med. 2000;342:145-153.
10. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
11. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. 2000;160:211-220.
12. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960-1991 [published correction appears in Hypertension. 1996;27:1192]. Hypertension. 1995;26:60-69.
13. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid? J Hum Hypertens. 1997;11:213-220.
14. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens. 1997;10:1097-1102.
15. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: Results from the health survey for England 1994. J Hypertens. 1998;16:747-752.
16. Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community. Do we need a wake-up call? Hypertension. 1999;34:466-471.
17. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: Analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
18. Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643.
19. Hebert LA, Kusek JW, Greene T, et al, for the Modification of Diet in Renal Disease Study Group. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension. 1997;30:428-435.
20. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: Results from the health survey of England 1998. Hypertension. 2001;38:827-832.
21. Ménard J, Chatellier G. Limiting factors in the control of BP: Why is there a gap between theory and practice? J Hum Hypertens. 1995;9(Suppl 2):S19-S23.
22. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender. Blood Press. 1995;4:313-319.
23. Wiklund I, Halling K, Rydén-Bergsten T, Fletcher A. Does the lowering of blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press. 1997;6:357-364.
24. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview. J Hum Hypertens. 2002;16(Suppl 2):S13-S16.
25. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
26. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999-2010.
27. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
28. Julius S, Kjeldsen SE, Brunner H, et al. VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544-548.